Navin Fluorine International is a fluorochemicals manufacturer that converts fluorspar into high-value fluorine chemistry across three earning verticals: High Performance Products (refrigerant gases such as R32), specialty chemicals (agrochemical intermediates made for global innovators), and CDMO services for pharma molecules, with a fourth advanced materials vertical being incubated for data centers, semiconductors and defense. The money is made at the intersection of a quota-constrained refrigerant business, campaign-based specialty manufacturing and contract pharma production, and the quality shows up in the numbers: consolidated EBITDA margin reached 34.2% in Q1 FY27, up 566 basis points year-on-year, after full-year FY26 margins of 32.6% on revenue of INR3,314 crores, up 41%. For a chemicals manufacturer, sustained margins above 30% are exceptional rather than average, and they have now held or improved for four consecutive quarters while revenue growth accelerated across every segment: HPP up 33% to INR540 crores, specialty up 48% to INR325 crores and CDMO up 82% to INR180 crores in Q1 FY27 alone.
The economics persist because of barriers that take years or regulation to replicate. In refrigerants, the right to produce rests on Kigali Protocol quota allocations that do not expand when competitors add plants, and no new Indian capacity is permitted after 2026, so the company's decision to build capacity against its full entitlement is structurally protected. Its integrated HF value chain, with 60,000 tons of AHF capacity across Surat and Dahej described as sufficient for four to five years, makes it the lowest-cost R32 producer in management's assessment, reinforced by roughly 60% renewable power once the captive project runs. In CDMO, customer qualification cycles and dedicated assets create lock-in: the cGMP4 plant was built around a European partner whose molecule keeps gaining geographic approvals, and a new MSA moves Navin one step deeper into that supply chain. In liquid cooling, it is the sole supplier and sole manufacturing site globally for Chemours' two-phase cooling fluid. The specialty business deliberately chases patented innovator molecules to avoid commoditized pricing, which is why agchem pressure has not dented gross margins holding near 58%.
The inflection is a wave of commissioned and imminent capacity converting into revenue over the next six quarters. Wave-1 (AHF plant commissioned February 2026, cGMP4 Phase-1 operationalized Q3 FY26) is already feeding FY26's 41% growth, and Wave-2 lands through FY27: the Chemours liquid cooling plant completes by end of Q2 FY27, the 15,000 MTPA R32 expansion (INR236.5 crores capex, INR600-825 crores peak annual revenue) and the Dahej MPP debottlenecking (INR75 crores capex, INR140-160 crores peak revenue) both commission in Q3 FY27, and cGMP4 Phase-2 (INR125 crores, fully dedicated to the European partner) operationalizes by Q4 FY27. Eighteen to twenty-four months out, the business should be running roughly 25,000 tons of R32 capacity against today's 9,000-10,000 tons, a doubled MPP asset turn, a CDMO unit crossing its $100 million revenue target this fiscal year with three molecules reaching FDA readout within 8-12 months, and an advanced materials platform with five customer-qualified products entering commercial-scale qualification from mid-Q4 FY27 via the INR90 crores adoption capex. Management guides consolidated EBITDA margins of 32-33% plus or minus 1% on that base.
The walk-talk record is unusually strong. In August 2025 management guided FY26 EBITDA margin at 25%; nine-month margins came in at 32% and the full year at 32.6%, a beat of roughly 700 basis points, and guidance has since been raised twice, to 28-30% and now 32-33%. Both AHF and cGMP4 Phase-1 were commissioned exactly as promised, Fermion supplies began January 2026 as committed, and FY26 revenue of INR3,314 crores exceeded the prior year by 41%. Capital allocation is conservative: all new capex is funded from internal accruals, the company turned net debt free during Q1 FY27 with operating cash flow of INR173 crores, working capital sits at 81 days against a 75-80 day frame, and net debt-to-equity was 0.01x at March 2026. The main slippage is Nectar utilization, now guided to 75-80% by end FY28 instead of full utilization because additional customer qualifications ran slower than planned.
The earnings path is visible: roughly INR740-985 crores of combined peak revenue potential from the two Q3 FY27 projects, a $100 million CDMO year, double-digit guided growth in HPP and specialty, and 70% of the FY26 margin expansion came from volumes rather than price, meaning leverage repeats as new assets fill. What must hold true is export absorption of incremental R32, since India stays oversupplied for five years and management will contract only 35-45% of capacity to keep open exposure to a global market where demand doubles over a decade while quota supply halves. The kill shot is the Chemours ramp: initial quarterly sales are around $1 million within a stated 15-month watch window, so if scale-up signals do not materialize by mid-FY28, the most strategically priced narrative loses its anchor, though the core refrigerant and CDMO engine would still carry the thesis.
companyname: Navin Fluorine International Limited ticker: NAVINFLUOR sector: Specialty fluorochemicals / Chemicals Navin Fluorine International Limited is a specialty fluorochemicals manufacturer founded in 1967 and part of the Padmanabh Mafatlal Group, one of India's oldest industrial houses. The company has spent nearly 60 years building expertise in fluorine chemistry, which is the common thread across all three business verticals. It operates four manufacturing units: Surat and Dahej in Guj...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion, order book surge
HFC capacity expansion of 15,000 MTPA of R32 expected to be commissioned in Q3 FY27 driven by new CAPEX projects
Guidance upgradedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Navin Fluorine International Limited and 4,900+ companies.
5-day free pass. No card required.